Compare Corcept Therapeutics Incorporated (CORT) vs Ascendis Pharma A/S (ASND) Stock

Corcept Therapeutics Incorporated (CORT) offers the better valuation at 43.5x trailing P/E (97.6x forward), making it the more compelling value choice. Analysts rate Corcept Therapeutics Incorporated (CORT) a "Buy" — based on 24 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Ascendis Pharma A/S is actually cheaper at 49.1x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Ascendis Pharma A/S (ASND) delivered a total return of +49.4%, compared to +40.2% for Corcept Therapeutics Incorporated (CORT). A $10,000 investment in ASND five years ago would be worth approximately $15K today (assuming dividends reinvested). Over 10 years, the gap is even starker: ASND returned +1246% versus CORT's +834.6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Ascendis Pharma A/S (ASND) is the lower-risk stock at 0.24β versus Corcept Therapeutics Incorporated's 1.12β — meaning CORT is approximately 378% more volatile than ASND relative to the S&P 500.

Corcept Therapeutics Incorporated (CORT) is the more profitable company, earning 13.1% net margin versus -31.7% for Ascendis Pharma A/S — meaning it keeps 13.1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CORT leads at 5.9% versus -18.9% for ASND. At the gross margin level — before operating expenses — CORT leads at 98.3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Ascendis Pharma A/S (ASND) trades at 49.1x forward P/E versus 97.6x for Corcept Therapeutics Incorporated — 48.6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CORT: 91.6% to $68.40.

None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Ascendis Pharma A/S (ASND) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.24), +1246% 10Y return). Both have compounded well over 10 years (ASND: +1246%, CORT: +834.6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.